[from Federal Register: May 3, 1996 (Volume 61, Number 87, Page 19910]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Application Concerning A Vaccine Against Gram-
Negative Bacterial Infections
AGENCY: U.S. Army Medical Research and Materiel Command, DOD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability for licensing of U.S. Patent Application Serial No. 08/
230,402 entitled ``Vaccine Against Gram-Negative Bacterial Infections''
and 20 April, 1994 and Foreign Patent Application PCT/US95/04446 filed
April 20, 1995. This patent has been assigned to the United States
Government as represented by the Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.
FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney,
(301) 619-2065 or telefax (301) 619-7714.
SUPPLEMENTARY INFORMATION: The invention relates to a vaccine which is
effective in inducing the production of antibodies with which to
immunize a second subject passively against infection by Gram-negative
bacteria and LPS-mediated pathology. The vaccine comprises a non-
covalent polyvalent complex formed between purified, detoxified LPS
derived from E. coli and purified outer membrane protein derived from
N. meningitidis. The same vaccine will also actively immunize a host
subject against Gram-negative bacterial infections and LPS-mediated
pathology. Meningococcal infections are included among those Gram-
negative bacterial infections protected against by the vaccine.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 96-11012 Filed 5-2-96; 8:45 am]
BILLING CODE 3710-08-M
from Federal Register: April 2, 1996 (Volume 61, Number 64, Page 14563
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Application Concerning Diagnosis of, and a
Vaccine Against, Dengue Virus
AGENCY: U.S. Army Medical Research and Materiel Command, DOD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability of U.S. Patent Application Serial No. 08/504,878 entitled
``Recombinant Vaccine Against Dengue Virus'', filed July 20, 1995, for
licensing. This patent has been assigned to the United States
Government as represented by the Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.
FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney,
(301) 619-2065 or telefax (301) 619-7714.
SUPPLEMENTARY INFORMATION: The invention describes methods of
production and purification of recombinant dengue virus envelope
proteins for use as diagnostic reagents or as vaccines and, when
combined, as a multivalent vaccine against all four dengue virus
serotypes. Each recombinant envelope protein was expressed by
baculovirus in insect cells and formed a particle which was purified.
This purification process consists of sonication of cell lysates and
differential centrifugations. Native antigenic and immunogenic
properties are maintained in the purified product. The vaccine is
designed for administration by subcutaneous, intramuscular or other
suitable routes or without adjuvant.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 96-7895 Filed 4-1-96; 8:45 am]
BILLING CODE 3710-08-M
[Federal Register: March 22, 1996 (Volume 61, Number 57, Page 11812-11813]
DEPARTMENT OF DEFENSE
Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Application Concerning a Method of Raising
Antibodies
AGENCY: U.S. Army Medical Research and Materiel Command, DOD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability of U.S. Patent Application Serial No. 08/460,617 entitled
``Method of Raising Antibodies Against E. coli of the Family CS4-CFA/
I'', and filed June 2, 1995, for licensing. This patent has been
assigned to the United States Government as represented by the
Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.
FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, (301) 619-2065 or telefax (301)
619-7714.
[[Page 11813]]
SUPPLEMENTARY INFORMATION: The invention provides a means of
immunization of humans with a peptide or denatured protein against
enterotoxigenic E. coli (ETEC) strains of the CS4-CFA/I family. The
antibodies raised by the peptides and proteins may be used as the basis
for a cross-reactive ETEC vaccine as well as diagnostic agents to
identify antigens of CS4-CFA/I bacteria.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 96-6929 Filed 3-21-96; 8:45 am]
BILLING CODE 3710-08-M
from Federal Register: March 14, 1996 (volume 61, number 51, page 10567
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Availability of Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Concerning a Microsphere Drug Application
Device
AGENCY: U.S. Army Medical Research and Materiel Command, DOD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability for licensing of U.S. Patent No. 5,470,311 entitled
``Microsphere Drug Application Device'' and issued on November 28,
1995. This patent has been assigned to the United States Government as
represented by the Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.
FOR FURTHER INFORMATION CONTACT:
Mr. Werten F.W. Bellamy, U.S. Army Intellectual Property Law Division,
901 North Stuart Street, ATTN: JALS-IP, Arlington, Virginia 22203-1837,
voice phone (703) 696-8119 or telefax (703) 696-8116.
SUPPLEMENTARY INFORMATION: The invention includes an apparatus and
methods for dispensing medicinals encapsulated in a biodegradable
polymer in surgical and other wounds. The apparatus, a microcapsule
drug applicator, allows the caregiver to implant or spread measured and
uniform quantities of microencapsulated medicinals in or on surgical or
traumatic wounds to prevent and/or treat infections. Specific examples
where microencapsulated antibiotics may prove useful include: soft-
tissue wounds; following debridement and reduction or fixation of open
fractures; to osteomyelitic bone after surgical debridement; after
surgical insertion of prostheses such as hip/knee replacements
(arthroplasty); and following vascular surgery or grafting.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 96-6044 Filed 3-13-96; 8:45 am]
[Federal Register: March 14, 1996 (Volume 61, Number 51, Page 10567]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Availability of Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Concerning a Test for Quantitative Thrombin
Time
AGENCY: U.S. Army Medical Research and Materiel Command, DOD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability for licensing of U.S. Patent No. 5,476,771 entitled ``Test
for Quantitative Thrombin Time'' and issued on December 19, 1995. This
patent has been assigned to the United States Government as represented
by the Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.
FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, (301) 619-2065 or telefax (301)
619-7714.
SUPPLEMENTARY INFORMATION: The invention is a quantitative method for
determining the plasma levels of thrombin-specific inhibitors which is
based on the quantitative thrombin time using plasma dilutions, excess
fibrinogen and thrombin. The plasma dilutions and excess fibrinogen act
in concert to eliminate the effect that coagulopathies have on standard
coagulation tests. The method is relatively simple and provides
superior results to standard conventional tests. The method is suitable
for performance in clinical hematology laboratories on a routine basis
using commercially availability instrumentation.
Gregory D. Showalter,
Army Federal Register, Liaison Officer.
[FR Doc. 96-6043 Filed 3-13-96; 8:45 am]
BILLING CODE 3710-08-M